Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rina-S Plus Standard of Care as Maintenance in Ovarian Cancer
NCT07859215Phase 3Not yet recruiting
- Sponsor
- Genmab
- Start
- Nov 2026
- Primary completion
- Mar 2030
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in ovarian cancer (2 arms), sponsored by Genmab. Primary endpoint: Progression-free Survival per RECIST Version 1.1 by Blinded Independent Central Review at 2 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07859215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859215.